You have accessJournal of UrologyInfections/Inflammation of the Genitourinary Tract: Prostate & Genitalia1 Apr 20131172 THE EFFICACY OF MIRODENAFIL FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME IN MIDDLE AGED PATIENTS Hyun Jun Park, Nam Cheol Park, Tae Nam Kim, and Jong Kil Nam Hyun Jun ParkHyun Jun Park Busan, Korea, Republic of More articles by this author , Nam Cheol ParkNam Cheol Park Busan, Korea, Republic of More articles by this author , Tae Nam KimTae Nam Kim Busan, Korea, Republic of More articles by this author , and Jong Kil NamJong Kil Nam Busan, Korea, Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.809AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES It has been speculated that PDE5 inhibitors may have an effect on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Mirodenafil is a newly developed, novel pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. The aim of this study was to investigate the efficacy of mirodenafil in middle aged patients with CP/CPPS. METHODS Eighty-eight men with CP/CPPS were randomized, in a single-blind fashion, to receive either levofloxacin (500mg/d)(group 1; 40 patients) or levofloxacin (500mg/d) and mirodenafil (50mg/d)(group 2; 48 patients) for 6 weeks. The International Prostate Symptom Score (IPSS), NIH chronic prostatitis symptom index (NIH-CPSI) and erectile function (EF) domain scores of the International Index of Erectile Dysfunction (IIEF) questionnaire were used to grade the symptoms at the baseline and 6 weeks into the study. RESULTS The mean ages of the two groups were 44.2±6.9 and 45.3±7.0 years, respectively. There was no significant difference between group 1 and 2 with regard to age, duration and scores of IPSS, NIH-CPSI and IIEF-EF domain at the baseline. Mirodenafil significantly improved the mean change from baseline in the IPSS at 6 weeks (group 1; −1.1 vs. group 2; −4.3, p<0.05). Significant improvements were also seen in the IPSS voiding subscore (group 1; −0.7 vs. group 2; −3.0, p<0.05). Larger changes from the baseline in the NIH-CPSI at 4 weeks were observed in group 2 (group 1; −3.2 vs. group 2; −7.2, p<0.05). Significant improvements were also seen in the NIH-CPSI voiding domains (group 1; −0.5 vs. group 2; −1.7, p<0.05) and the QoL domains (group 1;-1.0 vs. group 2;-1.8, p<0.05). Group 2 showed a greater increase in the IIEF-EF score and this difference was significant (group 1; +0.2 vs. group 2; +7.8, p<0.05). Commonly reported (1 case or greater) treatment adverse events in group 2 were frequent erections, dyspepsia, and headache (for each, 2 cases or less); however, no patient discontinued treatment due to adverse events. CONCLUSIONS Mirodenafil 50mg once daily was well tolerated and showed significant symptomatic improvements in middle aged patients with CP/CPPS. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e479 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hyun Jun Park Busan, Korea, Republic of More articles by this author Nam Cheol Park Busan, Korea, Republic of More articles by this author Tae Nam Kim Busan, Korea, Republic of More articles by this author Jong Kil Nam Busan, Korea, Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...